{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-096290","form_type":"8-K","ticker":"LAB","cik":"0001162194","company_name":"STANDARD BIOTOOLS INC.","filed_at":"2022-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.900704+00:00","generated_at":"2026-06-26T09:19:53.669815+00:00","sec_items":["1.01","1.02","3.02","5.03","3.03","5.02","5.07","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Fluidigm closes $225M convertible preferred financing, renames to Standard BioTools, appoints new CEO and board","bullets":["Closed $225M private placement of Series B convertible preferred to Casdin and Viking (112,500 shares each at $1,000/share).","Name changed from Fluidigm to Standard BioTools; authorized common shares doubled to 400M.","Appointed Michael Egholm as CEO/President and Hanjoon Alex Kim as COO; former CEO Linthwaite resigned.","Board expanded to 8; new directors: Eli Casdin, Martin Madaus, Frank Witney, and Michael Egholm.","Adopted 2022 Inducement Plan reserving 9.5M shares; granted Egholm options for 4.5M shares and Kim 1.6M shares at $3.99."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-096290","json":"https://secwatch.observer/filing/0001193125-22-096290.json","markdown":"https://secwatch.observer/filing/0001193125-22-096290.md","text":"https://secwatch.observer/filing/0001193125-22-096290.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1162194/000119312522096290/0001193125-22-096290-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1162194/000119312522096290/d314141d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T09:19:53.669815+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06ea6a3a64","claim":"Michael Egholm was appointed as Director at STANDARD BIOTOOLS INC..","evidence_excerpt":"the Board also appointed Michael Egholm as a Class I director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1162194/000119312522096290/0001193125-22-096290-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"36e54c206a","claim":"Martin Madaus was appointed as Director at STANDARD BIOTOOLS INC..","evidence_excerpt":"Viking has designated Martin Madaus as the Series B-2 Director and, accordingly, effective as of the Closing Date, the Board has appointed Dr. Madaus","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1162194/000119312522096290/0001193125-22-096290-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"70eccbd307","claim":"Stephen Christopher Linthwaite resigned as Director at STANDARD BIOTOOLS INC..","evidence_excerpt":"Stephen Christopher Linthwaite, Ana K. Stankovic and Nicolas M. Barthelemy each resigned from the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1162194/000119312522096290/0001193125-22-096290-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"7cece09208","claim":"Eli Casdin was appointed as Director at STANDARD BIOTOOLS INC..","evidence_excerpt":"Casdin has designated Eli Casdin as the Series B-1 Director and, accordingly, effective as of the Closing Date, the Board has appointed Mr. Casdin to serve as the Series B-1 Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1162194/000119312522096290/0001193125-22-096290-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d609dfd045","claim":"Frank Witney was appointed as Director at STANDARD BIOTOOLS INC..","evidence_excerpt":"the Board also appointed Dr. Frank Witney to the Board to serve as a Class III director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1162194/000119312522096290/0001193125-22-096290-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e3d5ddc846","claim":"Ana K. Stankovic resigned as Director at STANDARD BIOTOOLS INC..","evidence_excerpt":"Stephen Christopher Linthwaite, Ana K. Stankovic and Nicolas M. Barthelemy each resigned from the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1162194/000119312522096290/0001193125-22-096290-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"eb121908da","claim":"Nicolas M. Barthelemy resigned as Director at STANDARD BIOTOOLS INC..","evidence_excerpt":"Stephen Christopher Linthwaite, Ana K. Stankovic and Nicolas M. Barthelemy each resigned from the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1162194/000119312522096290/0001193125-22-096290-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}